Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
R B WarrenAndrew BlauveltY PoulinS BeeckM KellyT WuZ GengCarle F PaulPublished in: The British journal of dermatology (2020)
At week 52, risankizumab demonstrated superior efficacy and similar safety with less frequent dosing compared with secukinumab.